News Center

位置：

Honors Announcement

Group News

Media Reports

Shisi Pharmaceutical Group Named a “2025 Outstanding Competitiveness Listed Company in the Greater Health Sector”

Category:

Group News

发布时间：2025-12-13

【概要描述】 At this pivotal moment as the Hainan Free Trade Port is poised to launch island-wide closed-loop operations, the 14th China Listed Companies Summit and Hainan Free Trade Port Openness Opportunities Exchange Conference, hosted by Daily Economic News, was grandly inaugurated in Haikou on December 12, 2025. Guests from domestic and international capital markets, along with industry experts and academics, engaged in lively discussions centered on expanding new avenues for cooperative development and sharing the fresh opportunities presented by the Free Trade Port. During the summit’s 2025 Capital Markets Honor Gala, Shisiyao Group (02005.HK) was successfully shortlisted for the 2025 Listed Companies Reputation Ranking, thanks to its innovative products in the greater health sector and its steady performance in the capital markets.

Shisi Pharmaceutical Group Named a “2025 Outstanding Competitiveness Listed Company in the Greater Health Sector”

On the momentous occasion of the imminent launch of island-wide closed-loop operations at the Hainan Free Trade Port, the 14th China Listed Companies Summit and Hainan Free Trade Port Openness Opportunities Exchange Conference, hosted by Daily Economic News, was grandly inaugurated in Haikou on December 12, 2025. Guests from domestic and international capital markets, along with industry experts and academics, engaged in lively discussions centered on expanding new avenues for cooperative development and sharing the fresh opportunities presented by the Free Trade Port. During the summit’s 2025 Capital Markets Honor Gala, Shisiyao Group (02005.HK) was honorably recognized as a “Top-Performing Listed Company in the Greater Health Sector” on the 2025 Listed Companies Reputation List, thanks to its innovative products in the greater health field and its steady performance in the capital markets, thereby further underscoring the company’s sustained growth capabilities and broad market recognition.

“The Listed Company with Outstanding Competitiveness in the Greater Health Sector” is one of the series of rankings under the “2025 Listed Companies Reputation List” initiative launched at this summit. The theme of the “2025 Listed Companies Reputation List” is “Innovating the Future through Intelligence, Leading with Value,” and it aims to identify benchmark listed companies that drive industrial transformation through technological innovation, create long-term value through outstanding corporate governance, and demonstrate resilience and influence in global competition. The selection process focuses on a company’s overall performance across key dimensions, including value creation and returns, investment in innovation, technological breakthroughs, commercialization of research outcomes, global expansion, and social responsibility, thereby recognizing these listed companies’ leading role and exceptional achievements in China’s economic transformation, upgrading, and sustainable development.

Shisiyao Group is firmly committed to the paramount task of high-quality development, with a focus on strengthening the domestic market and ensuring smooth dual circulation—both domestic and international. The company is deeply implementing an innovation-driven strategy, continuously promoting the deep integration and coordinated development of the innovation chain, talent chain, industrial chain, and supply chain, and steadily fostering and expanding new drivers of productivity. As a result, Shisiyao has established an industrial ecosystem characterized by innovative pharmaceuticals as the leading force, specialty chemical drug formulations and active pharmaceutical ingredients as the core, and high-end pharmaceutical packaging materials and distinctive bioproducts as extensions.

Empowered by robust advances in technological innovation and digital transformation, Shisiyao Group has consistently ranked among the industry leaders in recent years in terms of the number of new products submitted for approval and subsequently approved. To date, a total of 165 drug varieties comprising 216 dosage forms have either passed or been deemed to have passed the bioequivalence and therapeutic equivalence evaluation for generic drugs, with 32 of these dosage forms receiving approval nationwide ahead of others. The group now boasts 91 active pharmaceutical ingredient (API) varieties, and its integrated “API-plus-formulation” development model has yielded remarkable results, further strengthening the foundation for innovative, high-quality growth and driving a significant leap in both its innovation influence and market competitiveness.

Behind these numerous innovative achievements lies Shisi Pharmaceutical Group’s keen ability to seize market opportunities. In the recently concluded 11th round of national centralized drug procurement, the Group had a total of 12 products across 14 specifications selected; in the recently launched follow-up procurement by the Guangdong Provincial Drug Alliance, 135 product specifications were successfully renewed. Moreover, in the upcoming list of renewal candidates for drugs covered under the first through eighth rounds of nationally organized centralized procurement, the Group has 47 items included. This series of innovations and successful market access has built strong momentum for the company to consolidate its existing market share and explore new growth opportunities, while also injecting fresh impetus and confidence into the capital markets.

The China Listed Companies Summit is an annual financial forum hosted by Daily Economic News, a leading domestic financial media outlet. Since its inception in 2011, the summit has been successfully held for fourteen consecutive sessions. It brings together renowned economists from China and abroad, senior executives of listed companies, and representatives of institutional investors to discuss developments in the capital markets and pressing economic issues, serving as a highly influential dialogue platform within the industry.

Keywords:

Expanding Employment Opportunities through University-Enterprise Collaboration | Shijiazhuang No. 4 Pharmaceutical Group and the School of Foreign Languages at Hebei University of Economics and Business Launch In-Depth University-Enterprise Cooperation

Shijiazhuang Sihua Pharmaceutical: As Low-Temperature Snowfall Strikes, We Are Fully Committed to Safeguarding the “Lifeline” of Pharmaceutical Supply